Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Shares Outstanding (Diluted Average) (2016 - 2023)

Apyx Medical's Shares Outstanding (Diluted Average) history spans 14 years, with the latest figure at $34.6 million for Q4 2023.

  • For Q4 2023, Shares Outstanding (Diluted Average) changed 0.31% year-over-year to $34.6 million; the TTM value through Dec 2023 reached $34.6 million, changed 0.31%, while the annual FY2023 figure was $34.6 million, 0.31% changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $34.6 million in Q4 2023 per APYX's latest filing, roughly flat from $34.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $34.6 million in Q4 2023 to a low of $34.1 million in Q4 2019.
  • Average Shares Outstanding (Diluted Average) over 5 years is $34.4 million, with a median of $34.3 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): fell 0.86% in 2019, then grew 0.54% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $34.1 million in 2019, then rose by 0.42% to $34.2 million in 2020, then increased by 0.35% to $34.3 million in 2021, then grew by 0.54% to $34.5 million in 2022, then increased by 0.31% to $34.6 million in 2023.
  • Per Business Quant, the three most recent readings for APYX's Shares Outstanding (Diluted Average) are $34.6 million (Q4 2023), $34.5 million (Q4 2022), and $34.3 million (Q4 2021).